PATENT CLAIM ANALYSIS

Application Number: 16123167
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2018-12
Patent Classification: ["514", "157000"]

Abstract:
Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.

Claim (Index 7):
The method of  claim 1 , wherein the Bcl-2 inhibitor is venetoclax or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 36.0
- Percentile: 97.0
- Lexical Diversity: 1.40909
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15183340', '16123203', '15628143', '15356014', '15075033']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.871095968881278
- 35 USC 102 Novelty (BERT): 0.7126162642795483
- Combined Prediction Score: 0.8552479984211051
- Mean Citation Score: 667.507446
- Max Citation Score: 801.40594
- Similarity Product: 751.0329922122763

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test